Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors
Authors:
- 1 March 2011
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (6) , 1601-1606
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Discovery and Preclinical Evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic Acid, (3S)-3-Morpholinylmethyl Ester (BMS-599626), a Selective and Orally Efficacious Inhibitor of Human Epidermal Growth Factor Receptor 1 and 2 KinasesJournal of Medicinal Chemistry, 2009
- Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Effects of Food on the Relative Bioavailability of Lapatinib in Cancer PatientsJournal of Clinical Oncology, 2009
- Thienopyrimidine-based dual EGFR/ErbB-2 inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Pharmacokinetics of gefitinib in humans: The influence of gastrointestinal factorsInternational Journal of Pharmaceutics, 2007
- Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase InhibitorsJournal of Medicinal Chemistry, 2007
- Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2006
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- Protein tyrosine kinase inhibitors as anticancer agentsExpert Opinion on Therapeutic Patents, 2004
- The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000